SCHEMBL30633686

SCHEMBL30633686

COC(=O)c1cc(=O)c2c(F)cc(Br)cc2n1C(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP3A4 P08684 1/20 0.46
MAPT P10636 4/20 0.38
NOTUM Q6P988 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.32
HPGD P15428 1/20 0.32
PTPN11 Q06124 1/20 0.32
LMNA P02545 2/20 0.31
TP53 P04637 1/20 0.31
NPC1 O15118 1/20 0.31
NFKB1 P19838 1/20 0.31
RAB9A P51151 1/20 0.31
NFKB2 Q00653 1/20 0.31
RELA Q04206 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
ACACB O00763 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26613912 1.00 ALDH1A1 (0.46) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL26613897 0.85 KDM4E (0.40) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL30633740 0.85 KDM4E (0.40) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL30633791 0.74 CDK4 (0.38) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL31257648 0.72 KDM4E (0.37) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL35210704 0.72 NOTUM (0.37) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL30633783 0.70 MCL1 (0.35) ALDH1A1CYP1A2CYP2C9CYP2C19MAPT
SCHEMBL26613922 0.70 MCL1 (0.35) ALDH1A1CYP1A2CYP2C9CYP2C19MAPT
SCHEMBL30633716 0.70 WDR5 (0.32)
SCHEMBL35210603 0.70 GAA (0.36) ALDH1A1KDM4ECYP3A4MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136586-A1 Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors BEIGENE, LTD. (KY) 2025-05-01 US disclosed
EP-4514797-A1 SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS BeiGene, Ltd. (KY) 2025-03-05 EP disclosed
CN-119053598-A Substituted 7- (pyrimidin-4-yl) quinolin-4 (1H) -one compounds as cyclin dependent kinase inhibitors 百济神州有限公司 2024-11-29 CN disclosed
WO-2023208172-A1 SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS BEIGENE , LTD. (KY) 2023-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136586-A1 Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors CDK4, CDK7, CDK8 ALDH1A1 2255/4885KDM4E 527/4885CYP1A2 3256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.